Atlas Trials

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Clinical trial NCT06986174 · RECRUITING

Trial details

NCT number
NCT06986174
Sponsor
Shayna Sarosiek, MD
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Waldenström MacroglobulinemiaLymphoplasmacytic LymphomaB-Cell Lymphoproliferative DisorderIndolent Lymphoma
Start date
2025-11-21
Primary completion
2028-10-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.